NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

Key Terms

intracranial EEG medical

A procedure that records electrical activity directly from the brain by placing tiny sensors on or under the skull, used when surface measurements aren’t detailed enough. It’s important to investors because results can drive demand for specialized medical devices, support clinical trial evidence for treatments such as epilepsy surgery or neurostimulation, and influence regulatory approvals and reimbursement—similar to how a detailed inspection report can determine whether a building renovation goes forward.

iEEG medical

Intracranial electroencephalography (iEEG) is a medical recording method that places tiny sensors directly on or in the brain to measure electrical activity. Think of it as putting microphones right on a concert stage to hear individual instruments instead of listening from the audience. For investors, iEEG matters because it underpins advanced diagnostics, surgical planning, and next‑generation medical devices and brain‑computer interfaces, which can drive clinical adoption, regulatory scrutiny, and commercial opportunity.

neuromodulation medical

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

idiopathic generalized epilepsy medical

Idiopathic generalized epilepsy is a form of epilepsy where recurring seizures arise across both sides of the brain without an identifiable structural cause, often linked to inherited factors. Think of it like a wiring issue that affects an entire house rather than a single appliance; seizures can take several typical forms (brief staring spells, muscle jerks, or full convulsions). For investors, it matters because prevalence, treatment options, ongoing drug and device trials, and regulatory progress drive demand, reimbursement, and commercial opportunity in the neurological and pharmaceutical markets.

Post-Approval Study regulatory

A post-approval study is a research program regulators require or companies choose to run after a drug or medical device is already approved and sold, to track real-world safety, longer-term effectiveness, or performance in broader patient groups. Investors care because results can change product labels, sales forecasts, or trigger additional costs and restrictions—think of it as a warranty-era check that can alter a product’s market value and legal risk.

GTC seizure medical

A GTC seizure is a generalized tonic‑clonic seizure, a major type of convulsive episode where abnormal electrical activity affects the whole brain, causing loss of consciousness, body stiffening and rhythmic jerking. For investors, mentions of a GTC seizure in drug or device reports signal a serious safety event that can pause clinical trials, trigger regulatory scrutiny, increase liability risk, and materially affect a company’s valuation — like a major safety recall for a consumer product.

--Data presentations to feature 18-month NAUTILUS results and new Post Approval Study (PAS) analyses on GTC seizure reduction--

--RNS^® System to be featured in over 80 scientific presentations and posters, the most of any neuromodulation therapy--

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System and NeuroPace AI platform will be prominently featured at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia where NeuroPace will feature new clinical and AI-driven advances that underscore the Company’s focus on delivering life-changing outcomes and enabling physicians to provide more confident, data-informed care for people living with epilepsy.

“Our presence at AES this year is about demonstrating life-changing, durable outcomes with the RNS System and how those outcomes are enabled by the depth and quality of our data,” said Martha Morrell, MD, Chief Medical Officer at NeuroPace. “New analyses for the RNS System Post-Approval Study for focal epilepsy, together with emerging results from the NAUTILUS study for idiopathic generalized epilepsy, demonstrate that responsive neuromodulation can deliver meaningful and sustained seizure reductions for patients. At the same time, the intracranial EEG data recorded by the RNS System is fueling AI-driven tools that help physicians treat with more confidence than ever before.”

In addition to long-term outcomes data, NeuroPace will provide a first look at next-generation NeuroPace AI and SeizureID™¹ tools under development, which are being developed to transform intracranial EEG (iEEG) recordings into actionable insights that simplify epilepsy care. These tools are being designed to help clinicians review electrographic seizures, identify seizure patterns, and optimize RNS therapy programming – turning data into an asset that supports more confident decision-making at every visit.

“RNS therapy uniquely combines best-in-class outcomes with a rich, longitudinal iEEG dataset,” said Joel Becker, President and Chief Executive Officer of NeuroPace. “Our strategy is to leverage that dataset – and our growing AI capabilities – to build a differentiated platform for epilepsy care. AES is an ideal venue to demonstrate how our evidence, our technology and our AI roadmap are coming together to set a new standard for responsive neuromodulation.”

Scientific and Educational Highlights at AES 2025

Key NeuroPace-related presentations and activities planned for AES include:

Post-Approval Study (PAS) Data

• New analyses from the RNS System PAS, including additional detail on seizure reduction durability at three years and beyond, and prolonged periods of GTC seizure freedom in many patients.
• Multiple posters and presentations highlighting real-world outcomes and quality-of-life results across diverse drug-resistant focal epilepsy populations.

NAUTILUS Trial - 18-Month Preliminary Safety and Efficacy Results

• Updated data from the NAUTILUS clinical trial, the first and only study to evaluate responsive thalamic stimulation for the treatment of idiopathic generalized epilepsy (IGE), including 18-month safety and efficacy outcomes.

NeuroPace AI & SeizureID

• Demonstrations of NeuroPace AI and SeizureID in the NeuroPace booth and tech suite, illustrating how iEEG insights can streamline clinic workflows and support confident treatment decisions.

Clinical Evidence Leadership

• 11 NeuroPace posters on the RNS System and more than 20 sessions featuring RNS therapy, underscoring NeuroPace’s commitment to generating high-quality evidence and advancing the understanding of neuromodulation for epilepsy.

Featured AES Events Sponsored by NeuroPace

Product Theater – Transforming Epilepsy Care with the RNS System

• Sunday, December 7, 2025
• 2:30 – 3:30 p.m.
• Large Product Theater | Exhibit Hall, Georgia World Congress Center
• Featured Speakers:
  • Martha Morrell, MD, FAES – Clinical Professor of Neurology, Stanford University; Chief Medical Officer, NeuroPace
  • Kathryn Davis, MD, MSc, FAES – Associate Professor of Neurology, University of Pennsylvania; Director, Penn Epilepsy Center
  • Patricia Dugan, MD – Professor of Neurology, NYU Grossman School of Medicine; Director, Adult Epilepsy, NYU Langone Health
• Session Focus: Eighteen-month outcomes from the NAUTILUS trial, including clinically meaningful seizure reductions in IGE, and an overview of how NeuroPace is using AI to develop next-generation tools that advance epilepsy care.

Discover How RNS System Therapy Can Strengthen Your Epilepsy Practice

• Saturday, December 6, 2025
• Session Focus: Best practices from experienced RNS centers on clinic qualifications, patient selection and operational workflows for building a thriving responsive neuromodulation program.

Stimulation with a Strategy: Latest Advances in Neuromodulation

• Sunday, December 7, 2025
• Session Focus: Evolving strategies in network stimulation for focal epilepsy and how the RNS System is advancing the treatment of epilepsy.

Visit NeuroPace at AES

Throughout the meeting, members of the NeuroPace team will be available at Booth #125 and in the NeuroPace tech suite to provide hands-on demonstrations of the RNS System, NeuroPace AI and SeizureID, and to discuss how to integrate responsive neuromodulation into clinical practice. Attendees can pre-book demonstrations and view a full list of NeuroPace-related presentations at https://www.neuropace.com/december-conference-2025-epilepsy/.

About NeuroPace, Inc.

Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. NeuroPace may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding: NeuroPace’s expectations, forecasts and beliefs with respect to potential indication expansion for its RNS System and its software, technology and other product development efforts; increasing access to and adoption of RNS therapy as the standard of care in drug-resistant epilepsy; the impact that its new product development, including AI-based software suite, NeuroPace AI™ and Seizure ID™, will bring to patients and physicians who prescribe the RNS System. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: actual operating results may differ significantly from any guidance provided; uncertainties related to market acceptance and adoption of NeuroPace’s RNS System; risks related to regulatory compliance and expectations for regulatory submissions and approvals to expand the market for NeuroPace’s RNS System, including risks related to the NAUTILUS clinical trial; risks related to product development, including risks related to the development of AI-powered software, including NeuroPace AI™ and Seizure ID™ and the next generation device platform; risks related to NeuroPace’s reliance on contractors and other third parties, including single-source suppliers and vendors; and other important factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in NeuroPace’s public filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 4, 2025, as well as any other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.

¹For demo purposes only. Seizure ID is under FDA review, is not approved, and is not commercially available in the US. Nothing in this announcement should be interpreted as a claim regarding safety or effectiveness.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251202649264/en/

Investor Contact:

Scott Schaper

Head of Investor Relations

sschaper@neuropace.com

investors@neuropace.com

Source: NeuroPace, Inc.